Improving tech, treatment and care for people with Type 1 diabetes

NHS England and NHS Improvement have issued a letter Improving tech, treatment and care for people with Type 1 diabetes. This letter provides an update on the uptake of flash glucose monitors and other planned technological innovations to improve the treatment and care of people with Type 1 diabetes.

The letter can be viewed at NHS England

See also: NHS England press release: Tens of thousands given life changing diabetes monitors thanks to the NHS Long Term Plan

Manchester research: Activity trackers can be useful tools in managing diabetes

University of Manchester|  October  2019 | Activity trackers can be useful tools in managing diabetes

Experts at The University of Manchester have conducted the largest review so far of the effect of movement-monitoring devices, accelerometers and pedometers, on the activity of individuals with diabetes and cardiovascular disease.

The review included data from 36 studies, with more than 5000 participants, researchers investigated the short-term effects of using wearable step-counting devices on the physical activity in adults with cardiometabolic conditions, such as type 2 diabetes, and cardiovascular disease (CVD). They found the devices were associated with small-to-medium improvements in physical activity.

Results from previous studies have shown that the use of pedometers helps patients

activity-fitness-footwear-1556710.jpg

with chronic conditions to increase their physical activity levels. However, the authors of this paper note that a major limitation from previous studies is that interventions involving step-counting devices vary a lot, so it is unclear which interventions are most effective.

Dr Alex Hodkinson, one of the researchers who carried out the study, said; “This study differs to earlier ones because it has looked at which types of interventions using the two most common monitoring devices (accelerometers and pedometers) are most effective in improving physical activity among people with diabetes and cardiometabolic conditions.” (Source: University of Manchester).

Activity trackers can be useful tools in managing diabetes [press release]

The article is available from JAMA Network Open 

 

 

National Pregnancy in Diabetes Audit

National Pregnancy in Diabetes (NPID) audit report 2018 | The Healthcare Quality Improvement Partnership

hands-2568594_1920.jpg

The National Pregnancy in Diabetes (NPID) audit measures the quality of antenatal care and pregnancy outcomes for women with pre-gestational diabetes.

This is the first year that a Quality Improvement Collaborative (QIC) has been incorporated into the NPID programme for 2018/19 with the aim of focusing on improvement activity.

Some of the key findings include:

  • Overall 7 out of 8 women were not well prepared for pregnancy
  • There has been an increase in the rate of admissions with hypoglycaemia for women with type 1 diabetes
  • Almost one in two babies had complications related to maternal diabetes which is mostly the result of large for gestational age (LGA) babies
  • Admissions to neonatal units are more common than in the general population.

Full report: National Pregnancy in Diabetes (NPID) Audit Report 2018

See also: NHS Digital resources

Black and ethnic minority people face inequality in diabetes treatment

University of Surrey | October 2019 | Black and ethnic minority people face inequality in diabetes treatment

A new study conducted by experts at the University of Surrey in collaboration with pharmaceutical company Eli Lilly and Company, reports that black and ethnic minority people are not as likely to be prescribed newer medication for Type 2 diabetes and they experience less adequate monitoring of their condition compared to their white peers. The researchers also identified an inequality of care for people from socially disadvantaged backgrounds with Type 2;  as patients from the most affluent socioeconomic groups were found to be significantly more likely to have annual monitoring of their condition.

 

 

The underlying aim of the research was to evaluate contemporary data as to whether disparities exist in glycaemic control, monitoring, and prescribing in people with T2D. The research team analysed data collected from a nationally representative network of primary care practices (n= 164) across England for the last five years. Ethnicity was defined using the Office for National Statistics ethnicity categories: White, Mixed, Asian, Black, and Other (including Arab people and other groups not classified elsewhere).

The experts found disparities in glycaemic control, disease monitoring, and prescribing between ethnicities and socioeconomic groups, and a weak difference between the sexes.

Researchers found that black individuals were 50 percent less likely than white individuals to be prescribed newer medication, such as ‘SGLT2 inhibitors’ and ‘GLP-1 agonists’ that are used to lower blood sugar and have other benefits on the cardiovascular system. Those from an Asian background were 15 percent less likely than white people to be prescribed insulin and 50 percent less likely to be prescribed GLP-1 agonists (Source: University of Surrey).

Full press release available from University of Surrey

Journal article available from PLOS Medicine 

In the news:

OnMedica UK research reveals racial inequalities in diabetes care